J. Craig Venter, Ph.D., describes biofuels, vaccines and foods from made-to-order microbes

Public release date: 25-Mar-2012 [ | E-mail | Share ]

Contact: Michael Bernstein m_bernstein@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6042

Michael Woods m_woods@acs.org 619-525-6268 (March 23-28, San Diego Press Center) 202-872-6293 American Chemical Society

SAN DIEGO, March 25, 2012 Just as aspiring authors often read hundreds of books before starting their own, scientists are using decades of knowledge garnered from sequencing or "reading" the genetic codes of thousands of living things to now start writing new volumes in the library of life. J. Craig Venter, Ph.D., one of the most renowned of those scientists, described the construction of the first synthetic cell and many new applications of this work today at the 243rd National Meeting & Exposition of the American Chemical Society (ACS), the world's largest scientific society, which is underway this week.

In a plenary talk titled, "From Reading to Writing the Genetic Code," Venter described a fundamental shift in his field of genomics, and its promise for producing synthetic life that could help provide 21st century society with new fuels, medicines, food and nutritional products, supplies of clean water and other resources. Venter, a pioneer in the field, led the team at Celera Genomics that went head-to-head with the government-and-foundation-funded Human Genome Project in the race to decode the human genome. This quest, in which the 23,000 human genes were deciphered, ended with the teams declaring a tie and publishing simultaneous publications in 2001.

"Genomics is a rapidly evolving field and my teams have been leading the way from reading the genetic code deciphering the sequences of genes in microbes, humans, plants and other organisms to writing code and constructing synthetic cells for a variety of uses. We can now construct fully synthetic bacterial cells that have the potential to more efficiently and economically produce vaccines, pharmaceuticals, biofuels, food and other products."

The work Venter described at the ACS session falls within an ambitious new field known as synthetic biology, which draws heavily on chemistry, metabolic engineering, genomics and other traditional scientific disciplines. Synthetic biology emerged from genetic engineering, the now-routine practice of inserting one or two new genes into a crop plant or bacterium. The genes can make tomatoes, for instance, ripen without softening or goad bacteria to produce human insulin for treating diabetes. Synthetic biology, however, involves rearranging genes on a much broader scale that of a genome, which is an organism's entire genetic code to reprogram entire organisms and even design new organisms.

Venter and his team at the not-for-profit J. Craig Venter Institute (JCVI), which has facilities in Rockville, Maryland, and San Diego, announced in 2010 that they had constructed the world's first completely synthetic bacterial cell. Using computer-designed genes made on synthesizer machines from four bottles of chemicals, the scientists arranged those genes into a package, a synthetic chromosome. When inserted into a bacterial cell, the chromosome booted up the cell and was capable of dividing and reproducing.

In the ACS talk, Venter described progress on major projects, including developing new synthetic cells and engineering genomes to produce biofuels, vaccines, clean water, food and other products. That work is ongoing at both JCVI and at his company, Synthetic Genomics Inc. (SGI). A project at SGI for instance, aims to engineer algae cells to capture carbon dioxide and use it as a raw material for producing new fuels. Another group uses synthetic genomic advances with the goal of making influenza vaccines in hours rather than months to better respond to sudden mutations in those viruses.

Venter also described his work in sequencing the first draft human genome in 2001 while he and his team were at Celera Genomics, as well as the work on his complete diploid genome published in 2007 by scientists at JCVI, along with collaborators at The Hospital for Sick Children in Toronto and the University of California, San Diego. In addition to continued analysis of Venter's genome, he and his team are also studying the human microbiome, the billions of bacteria that live in and on people, and how these microbes impact health and disease.

Originally posted here:
J. Craig Venter, Ph.D., describes biofuels, vaccines and foods from made-to-order microbes

Professor leaves positive legacy

By Stephen Brooks | Originally Published: 1 hour ago |Modified: 1 hour ago |

Biochemistry professor Rawle Hollingsworth in his lab on Wednesday March 9, 2005.

During biochemistry professor Rawle Hollingsworths nearly 30 years at MSU, Tom Sharkey, chair of the biochemistry and molecular biology department, remembers having many conversations with him during casual run-ins outside the office.

One encounter sticks out in Sharkeys mind, who said he has a strong memory of listening to Hollingsworth explain carbohydrate involvement in blood types one day in the parking lot.

I was just fascinated to learn the things he was explaining, Sharkey said. Its just one of those moments in time that get frozen for reasons that you dont really know why.

Hollingsworth, a 55-year-old Haslett, Mich. resident, died from a pulmonary embolism on Feb. 29.

After completing his doctorate at the University of the West Indies in the Caribbean, Hollingsworth started as an assistant professor at MSU in 1983 and climbed the ranks to become a full professor.

I would say his enthusiasm really was the thing I continually think about when I think of him, Sharkey said.

Rawle Hollingsworth met his wife, Saleela Hollingsworth, at the University of the West Indies. The two were married for 26 years and had two children, Misha, 20, and Akhil, 15.

Saleela Hollingsworth said her husband loved traveling, reading and music and always put the childrens interests first.

View post:
Professor leaves positive legacy

Anatomy of Atomi

ANDREW Tan and his Japanese wife, Mitsuko Murano, found it difficult to find products in Singapore that matched their eclectic tastes and eye for standout designs.

But each time they visited Muranos hometown in Tokyo, they would go on a shopping spree.

Then they thought Why not bring these products to Singapore and open a shop?

Tan ditched his high-flying career at global accounting firm Ernst & Young and Murano gave up her job at an international cosmetic company to start Atomi, which, incidentally, stands for Andrew and Mitsuko in Japanese.

The philosophy behind our store is to promote Japanese design and comfortable lifestyle, says the sweet-natured Murano.

We started out with things we like, products weve been using for a long time that were confident about.

Atomi had a humble start, opening in November 2009 with only five brands to showcase. The couple handpicked products with timeless designs, meticulous handiwork, and those only found in limited quantities or editions. Today, the store offers more than 20 brands including a slew of award-winning designs.

We want to sell something that lasts a long time and not pander to the buy-and-throw culture, explains Murano.

Hence our products are not driven by trends.

Atomi also wants to show their customers that niche, innovative products arent necessarily pricey. At the store, linen items are priced from S$13 (RM31) to S$338 (RM830), ceramic and glassware start at S$43 (RM105) while designer chairs are sold from S$990 (RM2,435) onwards

More here:
Anatomy of Atomi

Bone Marrow Stem Cell Therapy Trial – Clues, But No Answers

(RTTNews.com) - An important clinical trial, which evaluated the use of autologous bone-marrow-cell therapy in patients with chronic ischemic heart failure, has failed to meet the prespecified end points of improvement in most measures of heart function, according to the results presented at the American College of Cardiology 2012 Scientific Sessions.

The trial dubbed, FOCUS - a phase II study, is the largest study to date to investigate if a patient's own bone marrow cells improved myocardial perfusion, reduced left ventricular end-systolic volume or enhanced maximal oxygen consumption in patients with coronary artery disease or LV dysfunction, and limiting heart failure or angina. The FOCUS trial was undertaken by the National Heart, Lung, and Blood Institute-sponsored Cardiovascular Cell Therapy Research Network.

Ninety two patients with chronic ischemic heart disease , having a left ventricular ejection fraction of 45% or less, a perfusion defect by single-photon emission tomography, or SPECT, who were no longer candidates for revascularization, were enrolled in the trial. Sixty one patients in the study were administered bone marrow cells through transendocardial injections while thirty one patients were administered placebo.

An assessment of primary endpoints at 6 months has revealed that there is no statistically significant difference between the treatment group and placebo arm in left ventricular end-systolic volume assessed by echocardiography, maximal oxygen consumption, and reversibility on SPECT. The secondary outcomes, including percent myocardial defect, total defect size, fixed defect size, regional wall motion, and clinical improvement, also has not exhibited any difference between the two arms.

However, according to the study authors, exploratory analyses have revealed that left ventricular ejection fraction improved in the treatment group compared with the placebo group by 2.7%.

The authors, led by Emerson Perin, concluded that the findings provide evidence for further studies to determine the relationship between the composition and function of bone marrow product and clinical end points. Understanding these relationships will improve the design and interpretation of future studies of cardiac cell therapy, the authors noted.

The results were published online March 24 in the Journal of the American Medical Association.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Link:
Bone Marrow Stem Cell Therapy Trial - Clues, But No Answers

Another of the Early Cryonics Pioneers Cryopreserved

The first generation of the modern cryonics community, people who were middle-aged in the 1970s, is benefiting from the technologies and visions that they built. They founded a movement that has sustained itself for four decades in providing steadily improved cryopreservation services through organizations such as Alcor and the Cryonics Institute. The growth that would remake cryonics as from a non-profit community into a for-profit business with a healthy research and development arm has yet to happen, unfortunately, despite the clear need for the ability to preserve the brains and minds of those who will age to death before the advent of working rejuvenation biotechnology. But the present level of success is enough to provide a shot at renewed life in the future for the few who are determined enough and organized enough to take it.

I see that another of the early cryonics pioneers was cryopreserved recently:

Alcor Co-Founder Fred Chamberlain is Cryopreserved

Fred Chamberlain III who, with his wife Linda, incorporated Alcor in 1972, was cryopreserved by Alcor on March 22, 2012. One week earlier, Fred relocated from Florida to a Scottsdale hospice. This allowed us to watch over him and respond immediately when needed. We believe that Fred received an excellent cryopreservation. More details will be released later.

Linda Chamberlain has released a document to announce his cryopreservation and honor him.

Bon Voyage, Fred Chamberlain

Fred Chamberlain was a NASA-JPL electrical engineer working on the Mariner-Jupiter-Saturn mission in 1973 [and] was and is of absolutely critical importance to cryonics. While most people with more than a passing acquaintance with cryonics will associate his importance with the founding of Alcor, that is in reality only a surrogate marker for his deeper importance. Fred came on the scene in cryonics in what was unarguably its darkest hour. It had degenerated into little more than a fraudulent cult in California and, everywhere in the US, it had lost all vestiges of technical and scientific rigor.

When Fred discovered this in his role as Vice President of the Cryonics Society of California (CSC) he not only left CSC and founded Alcor, he and Linda Chamberlain established, for the first time anywhere, the practice of scientific, evidence based cryonics; cryonics based on the scientific method, on documentation of procedures, policies, cryopreservation protocols and rigorous patient case reports. He and Linda mandated not only scientific and technical accountability, but administrative, financial and legal accountability as well.

Until it does become an earnestly growing industry of many competing companies and millions of cryopreservations every year, cryonics can only work - in the sense of providing a good chance at safe preservation until such time as molecular nanotechnology and other advanced medical technologies can rebuilt and revive cryopreserved individuals - if the movement acts as a community. Maintaining the means of brain preservation for the long term is simply a new option in the general category of caring for elders whose bodies are failing them: this is something that well-balanced communities of humans have accomplished for a long time indeed. So provided that the cryonics movement can persevere as an ordinary, standard community of people with shared interests, as it has for the past 40 years, it should offer those who are cryopreserved a good chance of stability and safety for the decades between now and the advent of restorative technologies of the future.

But that growth is still a better option all round. So very many people go to the grave every day, people who might have chosen cryonics or plastination if those were options backed by a large, vocal industry with millions of customers.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Interview With Dmitry Itskov of Russia 2045

The founder of the Russia 2045 initiative is interviewed here: "Dmitry Itskov is the founder of Global Future 2045, which recently held its first conference. The Russian entrepreneur gathered scientists from around the world to discuss many topics that will help achieve one goal: life extension. ... The main idea of the project and my mission is to help people, to eliminate disease and death probably in the future, to overcome the limitations of our body, and to help humanity grow out of the crisis. As for my personal background, I have always been in the IT business, internet technologies. I published a few internet newspapers in Russia, I produce internet TV channel, a kind of blog service, email service, so being in this business I have always been interested in science and technologies that can extend life. Of course, like anybody, I have seen death and diseases in my family, my grandparents have gone, I've always been thinking how can I personally help. I've also been interested in science and I've seen an example of scientists who haven't gone, who are with us, like Stephan Hawking. He can't even move, he can't even normally talk to people, so this experience inspired me, this made me think how can I participate and help people. I decided to launch such an initiative with the help of Russian scientists who I knew like me. What helped me was that talking to them I was pretty sure that if we launched a kind of a big technical project, a big social initiative, if we work together, if we make our thinking global, and if we are able to launch a global network, then there is a very big chance we make our dreams come true. ... [The Avatar initiative] is the main technological project of the initiative which consists of four steps. One is human-like robot controlled by brain-computer interface. ... the second part is about producing life support system for the human brain. ... The third part is reverse engineering for the brain." The fourth step is to replace the biological brain with an artificial system that is more durable and extendable - which is a long way out, but something that has to be accomplished carefully and thoughtfully to be anything other than an expensive form of suicide that happens to leave behind a copy of the original you. Acceptable means include slowly replacing neurons one by one with nanomachinery that replicates their function and data storage whilst interfacing with the remaining brain tissue - but again, this sort of technology is a long way out from where we stand now, and there are many other challenges to be overcome along the way.

Link: http://sciencefiction.com/2012/03/19/exclusive-interview-with-dmitry-itskov-founder-of-global-future-2045/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Transdifferentiation to Simplify Generation of Cells to Order

Researchers are slimming down the process of generating specific types of cell to order, turning the multi-step induced pluripotency processes of the last couple of years into a single step: researchers "have succeeded in obtaining somatic stem cells from fully differentiated somatic cells. [Scientists] took skin cells from mice and, using a unique combination of growth factors while ensuring appropriate culturing conditions, have managed to induce the cells' differentiation into neuronal somatic stem cells. ... Our research shows that reprogramming somatic cells does not require passing through a pluripotent stage. Thanks to this new approach, tissue regeneration is becoming a more streamlined - and safer - process. ... One factor in particular, called Brn4, which had never been used before in this type of research, turned out to be a genuine 'captain' who very quickly and efficiently took command of his ship - the skin cell - guiding it in the right direction so that it could be converted into a neuronal somatic stem cell. ... This interconversion turns out to be even more effective if the cells, stimulated by growth factors and exposed to just the right environmental conditions, divide more frequently. ... Gradually, the cells lose their molecular memory that they were once skin cells. ... It seems that even after only a few cycles of cell division the newly produced neuronal somatic stem cells are practically indistinguishable from stem cells normally found in the tissue. ... So far, insights are based on experiments using murine skin cells; the next steps now are to perform the same experiments using actual human cells. In addition, it is imperative that the stem cells' long-term behaviour is thoroughly characterized to determine whether they retain their stability over long periods of time."

Link: http://www.mpg.de/5548755/stem_cells_skin_cells

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Ongoing Mining of Human Studies for Correlations Between Metabolic Markers and Longevity

A number of research groups have spent the past few years aggressively mining the population of ongoing human longevity studies, taking advantage of the falling cost of biochemical and genetic assays in order to conduct as many tests as they can: the more data the better. This has resulted in a steady stream of papers that report an increasing number of correlations between specific biological markers and longevity in human populations - though as noted in past posts here, these rarely hold up in different study groups, indicating a large number of tiny contributions to longevity, most of which vary greatly in their effects between human lineages. Metabolism is ferociously complex, and the metabolic aspects that determine natural human longevity no less so.

At this point, there is more pouring of data into the hopper and sorting it all into buckets than there is real progress in understanding - that comes later. Here are two recent examples of this sort of research publication:

Cortisol serum levels in familial longevity and perceived age: The Leiden Longevity Study

Cortisol levels are strongly associated with a person's health. Familial longevity and age assessment of facial photographs (perceived age) are both associated with morbidity and mortality. The present study aimed to investigate morning cortisol levels in familial longevity and the association of these levels with perceived age. ... Perceived age and serum morning cortisol levels were measured for 138 offspring from long-lived families and 138 partners from the Leiden Longevity Study. ... This study demonstrates that high levels of cortisol are associated with a higher perceived age. This association was attenuated in offspring from long-lived families compared to their partners, suggesting enhanced stress resistance in these subjects. Future research will be aimed at elucidating potential mechanisms underlying the observations in this study.

Family History of Exceptional Longevity Is Associated with Lower Serum Uric Acid Levels in Ashkenazi Jews

OBJECTIVES: To test whether lower serum uric acid (UA) levels are associated with longevity independent of renal function.

PARTICIPANTS: Long-lived individuals (LLI) of Ashkenazi Jewish ethnicity, their offspring and controls (without family history of longevity).

RESULTS: Offspring were less likely to have hyperuricemia and had lower UA levels than controls. ... Furthermore, significant association between UA levels in LLI and their offspring has been observed.

CONCLUSION: Offspring had lower UA levels than controls despite similar renal function, suggesting that other factors such as UA metabolism or renal tubular transport determine UA levels. The association between UA levels and longevity is particularly intriguing because UA levels are potentially modifiable with diet and drugs.

Interesting as these studies are - when you read through them in connection with the dozens of other correlation studies examining the biochemistry of human longevity - this is really all something of a sideshow. There is no such thing as useless knowledge in the long term, and this all goes towards the final complete understanding of human metabolism that will exist in the future, but it doesn't help us move any faster now towards the goals of engineered longevity. There is an existing, well-defined path towards the production of rejuvenation biotechnology, and that path is where the majority of funding and effort should go if we want to see a real impact on the future trajectory of our own longevity.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Update on Bacterial Aging

The aging of bacteria has been a topic of interest in the years since its discovery; firstly, it overturns the long-held assumption that bacteria are essentially immortal, and secondly it provides insight into the very early evolutionary origins of aging. Here is a recent update: "Evidence for aging in symmetrically dividing bacteria such as Escherichia coli has historically been conflicting. Early work found weak or no evidence. More recent studies found convincing evidence, but negative results are still encountered. Because bacterial aging is believed to result from non-genetic (e.g. oxidative) damage, we tested the possibility that the negative outcomes resulted from the lack of an extrinsic damage agent. We found that streptomycin, which produces mistranslated proteins that are more vulnerable to oxidation, was able to induce both damage and aging in bacterial populations. A dosage effect relating the level of damage to the concentration of streptomycin was observed. Our results explain the previous inconsistencies because all studies that failed to find evidence for bacterial aging did not use a damage agent. However, all studies that succeeded in finding evidence utilized fluorescent proteins as a visual marker. We suggest that aging in those studies was induced by the harmful effects of an extrinsic factor, such as of the proteins themselves or the excitation light. Thus, all of the previous studies can be reconciled and bacterial aging is a real phenomenon. However, the study and observation of bacterial aging requires the addition of an extrinsic damage agent."

Link: http://www.ncbi.nlm.nih.gov/pubmed/22422756

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Popular Press on Organ Regrowth

A BBC News article: "It might seem unbelievable, but researchers can grow organs in the laboratory. There are patients walking around with body parts which have been designed and built by doctors out of a patient's own cells. ... There is a pressing need. A shortage of available organs means many die on waiting lists and those that get an organ must spend a lifetime on immunosuppressant drugs to avoid rejection. The idea is that using a patient's own stem cells to grow new body parts avoids the whole issue of rejection as well as waiting for a donor. ... Dr Anthony Atala [has] made breakthroughs in building bladders and urethras. He breaks tissue-building into four levels of complexity. 1) Flat structures, such as the skin, are the simplest to engineer as they are generally made up of just the one type of cell. 2) Tubes, such as blood vessels and urethras, which have two types of cells and act as a conduit. 3) Hollow non-tubular organs like the bladder and the stomach, which have more complex structures and functions. 4) Solid organs, such as the kidney, heart and liver, are the most complex to engineer. They are exponentially more complex, have many different cell types, and more challenges in the blood supply. ... We've been able to implant the first three in humans. We don't have any examples yet of solid organs in humans because its much more complex. ... One of the problems when you move to larger organs is the getting the blood supply to work, connecting arteries, capillaries and veins to keep the organ alive. It is why some researchers are investigating 'decellularisation' - taking an existing donated organ, stripping out the original cells and replacing them with new cells from the patient who will receive the organ."

Link: http://www.bbc.co.uk/news/health-16679010

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Theorizing More Broadly on the Topic of the Evolution of Longevity

The evolution of aging and longevity is a field in which it's still comparatively easy to make a mark and carve out an area of new theory. For most species it is still the case that ideas on their longevity are comparative unsettled: why they live as long as they do, what mechanisms may have determined their life span, and how it all fits in to the bigger picture of metabolism and the evolution of specific biological processes. There is far more data than any one group of researchers could hope to organize in a lifetime, and new information continues to flood in ever faster as the biotechnology revolution unfolds.

At some point this rich wealth of data starts to give rise to hypotheses that are more holistic: evolution as a system of systems linked by feedback loops, thousands of species interacting with one another in any given biome, and the evolution of each species highly connected to that of its peers. Embarking upon this level of modeling and understanding, all the way down to biomolecular processes, will keep evolutionary biologists busy for the next century or so, I'd imagine - and give them something to do with the staggering levels of computing power that will be available by that time.

Here is an interesting open access paper that gives a hint of the shape of this sort of future research, whilst considering the evolution of longevity amongst interacting species:

Various organisms (i.e., bacteria, fungi, plants and animals) within an ecosystem can synthesize and release into the environment certain longevity-extending small molecules. Here we hypothesize that these interspecies chemical signals can create [selective] forces driving the ecosystemic evolution of longevity regulation mechanisms.

In our hypothesis, following their release into the environment by one species of the organisms composing an ecosystem, such small molecules can activate anti-aging processes and/or inhibit pro-aging processes in other species within the ecosystem. The organisms that possess the most effective (as compared to their counterparts of the same species) mechanisms for sensing the chemical signals produced and released by other species and for responding to such signals by undergoing certain hormetic and/or [cellular housekeeping related] life-extending changes to their metabolism and physiology are expected to live longer then their counterparts within the ecosystem.

Thus, the ability of a species of the organisms composing an ecosystem to undergo life-extending metabolic or physiological changes in response [to] chemical compounds released to the ecosystem by other species: 1) increases its chances of survival; 2) creates selective forces aimed at maintaining such ability; and 3) enables the evolution of longevity regulation mechanisms.

So the researchers propose that such things as the ability of rapamycin (produced by soil bacteria) to extend life in mice or the beneficial effects of mammalian bile acid on yeast life span are late manifestations of cross-species evolutionary processes that have been going on since the very earliest epoch of multicellular life. The suggestion is that we should expect there to be a wide range of compounds produced by varied species that will have some beneficial effect on the life span of another species (such as by improving cellular housekeeping processes), because the existence of such relationships between species is a fundamental characteristic of diverse ecosystems produced by evolution.

Which is an interesting line of thought, and I look forward to seeing where it leads.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Outsider's Overview of Cryonics, Part II

The second part of an article in CMAJ that shows off some of the subtle prejudices against cryonics that exist in the medical scientific community (such as in the choice of title) while attempting objectivity: "Although death and taxes are said to be the only two certainties in life, a small but vocal community takes issue with the inclusion of the former. There is, they say, the alternative of cryonics, in which a legally dead person is preserved at -196C in hopes that he will ultimately be revived and rejuvenated, once a cure for his ailment is found. And it's entirely consistent with the basic tenets of medicine, providers argue. ... Although it seems like an unusual and radical idea to many people, I think in the very truest sense of the term, this is conservative medicine. This is literally conserving a patient rather than giving up on them by today's standards of medicine. It's true a doctor can't do anything more for these people, but that doesn't mean the future cannot. ... Those interested in cryonics tend be optimistic, hopeful about technological developments and dissatisfied with an ordinary life span, says Ben Best, president of the Cryonics Institute. ... a miniscule chance is better than none, enthusiasts say. ... Nobody has come up with a better idea yet, so therefore myself, as well as some others, believe that cryonics is simply the second worst thing that can happen. You're going to die. You're going to stop breathing. Whether you be buried or cremated or cryopreserved, it's going to happen. There's nothing we can do about this now, but I know that if I'm cremated or buried, even if technology vastly increased, I'm never coming back. ... Enthusiasts are mystified that only a small segment of the general population has investigated the cryonic option. ... I don't know why there are far more people who don't sign up for cryonics arrangements. It's true that what we do is unorthodox and different, at least in 2012. But there are so many bizarre ideas out there which have no evidence to support them and get many, many people fascinated ... Yet we only have less than 1000 members after 40 years. ... People tend in my experience to kind of rely on this naturalistic [fallacy] that because people have always gotten older and died, therefore they should get older and die as a result of simply living longer."

Link: http://www.cmaj.ca/site/earlyreleases/20mar12_the-church-of-cryopreservation.xhtml

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

An Outsider’s Overview of Cryonics, Part II

The second part of an article in CMAJ that shows off some of the subtle prejudices against cryonics that exist in the medical scientific community (such as in the choice of title) while attempting objectivity: "Although death and taxes are said to be the only two certainties in life, a small but vocal community takes issue with the inclusion of the former. There is, they say, the alternative of cryonics, in which a legally dead person is preserved at -196C in hopes that he will ultimately be revived and rejuvenated, once a cure for his ailment is found. And it's entirely consistent with the basic tenets of medicine, providers argue. ... Although it seems like an unusual and radical idea to many people, I think in the very truest sense of the term, this is conservative medicine. This is literally conserving a patient rather than giving up on them by today's standards of medicine. It's true a doctor can't do anything more for these people, but that doesn't mean the future cannot. ... Those interested in cryonics tend be optimistic, hopeful about technological developments and dissatisfied with an ordinary life span, says Ben Best, president of the Cryonics Institute. ... a miniscule chance is better than none, enthusiasts say. ... Nobody has come up with a better idea yet, so therefore myself, as well as some others, believe that cryonics is simply the second worst thing that can happen. You're going to die. You're going to stop breathing. Whether you be buried or cremated or cryopreserved, it's going to happen. There's nothing we can do about this now, but I know that if I'm cremated or buried, even if technology vastly increased, I'm never coming back. ... Enthusiasts are mystified that only a small segment of the general population has investigated the cryonic option. ... I don't know why there are far more people who don't sign up for cryonics arrangements. It's true that what we do is unorthodox and different, at least in 2012. But there are so many bizarre ideas out there which have no evidence to support them and get many, many people fascinated ... Yet we only have less than 1000 members after 40 years. ... People tend in my experience to kind of rely on this naturalistic [fallacy] that because people have always gotten older and died, therefore they should get older and die as a result of simply living longer."

Link: http://www.cmaj.ca/site/earlyreleases/20mar12_the-church-of-cryopreservation.xhtml

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Vernor Vinge on Radical Life Extension

From an interview with Vernor Vinge at Wired: "First of all, I'm all for human life extension. In The Singularity is Near, I think, [Ray Kurzweil] has a nice discussion of the situation that a lot of essayists have where they say, 'Oh, we really don't want that. A wise and philosophical person realizes that life needs be limited, and that's a good thing,' these essayists say. He does a good job of criticizing that point of view, and I certainly agree with that. Furthermore, I think that a human lifespan of a thousand years with post-Singularity technology is easily doable. I think a lifespan of a thousand years would actually - Singularity aside - would do human society and human nature a great deal of good, and don't think it is that difficult, it probably can even be achieved without having a Technological Singularity. Life spans of 10,000 to 100,000 years, then you begin to look at what's involved, the humans that are involved, and how capable a human mind is of absorbing variety. ... The complaint or the criticism here is that the human mind has a certain level of ability to handle different sorts of complexity, and if you believe that you could go 100,000 years and not be turned into a repeating tape loop, well, then let's talk about longer period of time. How about a billion years, or a hundred billion years? At a hundred billion years, you're out there re-engineering the universe. The age of the universe becomes your chief longevity problem. But there's still the issue of, what would it be like to be you after that? This raises the point, which actually I'm sure is also on Ray's mind, that if you're going to last that long you have to become something greater, and the Singularity is ideally set up to supply that. So the people who are into the intelligence amplification mode of looking at these things, this all fits. And I'm not saying that in a critical and negative way, it does all fit, and it puts you in a situation where you are talking realistically about living very long periods of time, perhaps so long that you have to re-engineer the universe because the universe is not long-lived enough. At the same time, you have to be growing and growing and growing. I mean, intellectually growing. Now, if you look at that situation, it ultimately gets you, I think, to a very interesting philosophical point, which really I don't think was within the horizon of what people normally thought about two or three or four hundred years ago."

Link: http://www.wired.com/underwire/2012/03/vernor-vinge-geeks-guide-galaxy/

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

SENS5 Video: More on that General Method of Correcting Mitochondrial Mutations

Mitochondria crowd your cells, roving descendants of ancient bacteria that were long ago co-opted to serve as power plants, turning food into adenosine triphosphate (ATP), the energy store chemical used to power cellular machinery. As a legacy of their bacterial origins, mitochondria carry their own DNA, separate from that in the cell nucleus. Making ATP is a messy business, creating all sorts of reactive molecules as byproducts, and that mitochondrial DNA is more vulnerable than the safely enclosed nuclear DNA. The balance of evidence strongly implicates mitochondrial DNA damage as one of the contributing causes of aging. A damaged gene can no longer be used as a blueprint for the process of gene expression that produces the protein machinery that is vital to the operation of a mitochondrion, and from there matters only go downhill - it's a long road that ends up at atherosclerosis, neurodegeneration, and many other forms of advanced age-related degeneration.

Thus finding ways to repair mitochondrial DNA (mtDNA) is of great importance - but this is still a minority field of science in comparison to stem cell medicine or cancer research. Nonetheless, mitochondrial repair has been attracting some attention in the past week, as an important new line of research made it to the press release and publicity stage. The technique demonstrated is not really repair, per se, more a method of working around damage to mitochondrial genes - but it looks to be a great improvement over existing methodologies in terms of cost, time, and difficulty. This may enable broader and faster progress towards therapies that can remove the harm caused by damaged mitochondria. You might peruse these recent posts for more details on the work:

The new method is a way to deliver more or less arbitrary RNA to mitochondria, which should allow for continued function even after mutational damage to important genes. Production of RNA is a first step in the convoluted process of gene expression - by which genes are used as a blueprint for proteins - so it's quite possible to skip the gene and start with the RNA. This shortcut is the basis for a range of modern life science research, and one obvious use is to correct for a missing or damaged gene: find a way to provide the patient with an ongoing supply of suitably crafted RNA molecules targeted to the right places in his or her cells and it won't matter that the gene is broken.

I should note that there are only thirteen genes in the mitochondria that are important for the purposes of this discussion, but the process of producing repairs or workarounds for each one has been hard, very different for each of them, slow, and difficult up until this point. A method that works in a very similar way for all of them is a big deal.

The researchers presented on their work in RNA last year at SENS5, and I see that the SENS Foundation volunteers moved up the presentation video in the queue for processing and posted it to YouTube today:

A decline in the function of mitochondria may contribute to the aging process and age-related disorders. A functional decline could arise from accumulated mtDNA mutations over time, leading to reduced oxidative phosphorylation and other untoward effects on mitochondrial activities. Strategies that restore mitochondrial function could potentially offset key aspects of aging decline. RNA import into mammalian mitochondria is considered essential for replication, transcription, and translation of the mitochondrial genome but the pathway(s) and factors that control this import are poorly understood.

In recent studies we have shown a role for polynucleotide phosphorylase (PNPASE) in regulating the import of nuclear-encoded RNAs into the mitochondrial matrix. ... A mitochondrial RNA targeting signal was identified that enables the import of heterologous RNAs in a PNPASE-dependent manner. Combined, our studies show an unanticipated role for PNPASE in mediating the translocation of RNAs into mitochondria and provide a potential therapeutic route for halting or reversing the decline in mitochondrial function with aging.

In short, the researchers have found a mechanism that can be hijacked in order to import RNA into the mitochondria as desired.

Source:
http://www.longevitymeme.org/newsletter/latest_rss_feed.cfm

Study Reports Progress Against Fatal Brain Cancer

(HealthDay News) -- A new method to prevent recurrence of deadly glioblastoma brain cancer shows promise, say U.S. scientists.

Radiation can temporarily shrink a glioblastoma tumor, but the cancer nearly always recurs within weeks or months. Few people with this type of brain cancer survive more than two years after diagnosis.

In a study on mice, Stanford University School of Medicine researchers found that blocking access to oxygen and nutrients prevents tumor recurrence.

The first step, they said, was discovering that tumors blasted with radiation use a secondary pathway to generate blood vessels needed for regrowth.

"Under normal circumstances, this pathway is not important for growth of most tumors," senior author Martin Brown, a professor of radiology, said in a Stanford news release. "What we hadn't realized until recently is that radiation meant to kill the cancer cells also destroys the existing blood vessels that nourish the tumor. As a result, it has to rely on a backup blood delivery pathway."

The Stanford team used a molecule called AMD3100 to block the secondary glioblastoma tumor growth process in mice.

The study was published online Feb. 22 in the Journal of Clinical Investigation. Read more...

Immunice for Immune Support

Source:
http://feeds.feedburner.com/integratedmedicine

List of Companies in Biotechnology Sector

Biotechnology as the name implies is the combination of Bio and Technology. It is an area of biology which includes use of live organism and bio processes in engineering, technology. In short Biotechnology is technical application which can use live organism and biological system techniques to manufacture or change any product or process it for any specified type of use. Any Biotechnology Company or organization is a firm which uses biotechnology for manufacturing or designing any product or service.

List of Biotechnology Companies:

A. Companies in US

Abraxis Bioscience, Acorda Therapeutics, Alkermes, Amgen, Amylin Pharmaceuticals, Arena Pharmaceuticals, ArrayBioPharma, Avanir Pharmaceuticals, Biogen Idec, Carrington Laboratories, Celgene, Cephalon, Cerus, Coley Pharmaceutical Group, Cubist Pharmaceuticals, CuraGen, CV Therapeutics, Cytogen, Enzo Biochem, Enzon Pharmaceuticals, Genentech,GenVec, Genzyme, Gilead Sciences, Human Genome Sciences, Idenix Pharmaceuticals, Indevus Pharmaceuticals, InterMune, Inspire Pharmaceuticals, Imclone Systems, ImmunoGen, Isis Pharmaceuticals, Lexicon Pharmaceuticals, LifeCell, Ligand Pharmaceuticals, Maxygen, Medarex, Medivir Group, MedImmune, MGI Pharma, Micromet, Millennium Pharmaceuticals, Monogram Biosciences, Myriad Genetics, Nabi Bio pharmaceuticals, Nektar Therapeutics, Neurocrine Biosciences, NPSPharmaceuticals, Omrix Bio pharmaceuticals, Oscient Pharmaceuticals, OSI Pharmaceuticals, Palatin Technologies, PDLBioPharma, Pharmion, Progenics Pharmaceuticals, Regeneron Pharmaceuticals, Replidyne, Tanox, Targacept, Trimeris, United Therapeutics, Vertex Pharmaceuticals, ViaCell, ViroPharma, Xoma, ZymoGenetics.

B. Companies in India

Alembic Ltd, Amersham Pharmacia Biotech Asia-Pacific Ltd, Bharat Serums and Vaccines Ltd, Biocon, Biotech Consortium India Ltd, Brain Wave Bioinformatics Ltd, Catalyst Pharma Consulting, Chemitech Foundation, Colour-Chem Ltd, Dr Reddy’s Labs, Excel Industries Ltd, Haitanya Healthcare Ecom Ltd, Hi Tech Bio Labs, Landpower Biotech Ltd, Life Science Technology Lupin Ltd, Nicholas Piramal India Ltd, Ocimum Biosolutions Ltd, Serum Institute of India, Shantha Biotechnics Private Ltd.

C. Other companies

There are many other companies like Ambrilia Biopharma, AEterna Zentaris, Cangene, QLT, Bioniche Life Sciences (Canada),Protherics, Acambis, Vernalis (UK), Genmab, Bavarian Nordic (Denmark), Vitrolife (Sweden), MediGene, MorphoSys, GPC Biotech (Germany), Peptech, Life Therapeutics (Australia), IsoTis (Switzerland), Crucell (Netherlands), Sinovac Biotech (China),Innogenetics (Belgium) too in biotechnology.

Source:
http://www.biotechblog.org/rss.xml

Biotechnology, for the Upcoming Generations: Commercial Potential of a Complete for Profit and Growing Industry

Commerce is understood as any activity that creates wealth. For the past few decades, Biotechnology has been seen as an industrial means to generate wealth, most likely by adopting a ‘buying-selling’ model. Well!Biotechnology , in purest understanding, intends to tap a living process, most likely through gene manipulation, for contributing, directly or indirectly, towards improving the quality of human life. In the spate of economic struggle, states and corporations have started seeing Biotechnology as a core idea, systematized in a larger commercial cum industrial procedure for producing goods, to be sold for profit.

The Biotechnology products

Insulin has long been used by medics to control Diabetes. The recombinant protein is obtained from insulin secreting cultures, transformed through microbial bio techniques. As a matter of fact, some other approved products including antibiotics, fermented beverages, enzymes, bio degradable plastic etc. Are popularly used and now socially accepted. A longer list of newly researched products, still under development as a product line, is much waited for being introduced in the fast growing markets of developing nations. Moreover, the goods in this case are just not limited to be lifeless. The latest version of advancement through Biotechnology is to produce, in large-scale, germ plasm that grows into plant and live stock which is disease resistant and better yielding.

The sociopolitical resistance

People still have hunger pangs while food security bills are lingering in the Parliament. About a situation, when new concepts face allegations and non acceptance, there is nothing new. Genetically Modified food is often dismissed for harboring polluted DNA, once out for cultivation, would have no control from becoming promiscuous with the ‘natural’ variety. But why do we not resist the chemicals we have used for decades to voraciously grow crops and often ripen them artificially, with the same zest.

Well, the answer lies with us i.e. We dare to use the modern technology or bow before the conservative and orthodox methods. This is a fascinating field that has grown by leaps and bounds. Hence, we should look forward and seeing the advantages adopt Biotechnology with open hands.

Source:
http://www.biotechblog.org/rss.xml

Biotechnology Industry on the Brink: Healthcare Reform and Agricultural

Biotechnology industry expected to grow unceasingly

In spite of tremendous growth Biotechnology has shown in a short period, experts are of the opinion that all this growth witnessed so far is a tiny fragment of potential prospects of biotechnology. According to IBISWorld, $92 billion biotechnology is going to reach $146 billion by the year 2016.

Biotechnology: Unending source of new products

In spite of the fact that the industry is still in nascent stage, its products have already revolutionized medicine, agriculture and industries. Also, it must be remembered that there are hundreds of new products being developed in laboratories with promising results. When the market conditions were unfavorable, biotechnology start ups obtained funds from VC investments, which were eager to invest because of the high potential of the products being developed.

The companies also chose the route of mergers and acquisitions to leverage their core competencies and reduce costs in the period of unfavorable investor confidence during 2008 to 2010. Smaller companies merged with larger companies to get higher market shares and get access to resources. These developments have made biotechnology firms leaner and left them in better condition to proceed ahead with new efforts at research and development.

Another factor that is favoring the growth of biotechnology companies is the benefit of federal funding and support for biological defense projects. Pharmaceutical companies have acquired biotechnology firms in efforts to develop new formulations based on this revolutionary technology. Many companies are on the verge of breakthrough developments in developing drugs for conquering diseases like cancer and diabetes with the help of biotechnology.

Healthcare programs of federal government also support these companies to develop generic biological medicines and give them tax breaks. The role of biotechnology in improving the agriculture is evident; it offers solutions for increasing food production without degrading soil quality or posing threat to environment. The sustainable agriculture is clearly possible as shown by the new products and processes developed by biotechnology industry.

Conclusion:

With great promise of improved products in healthcare and agriculture, biotechnology is set to break its own record of tremendous growth seen so far!

Source:
http://www.biotechblog.org/rss.xml

The year of the dragon looks auspicious for Australian Biotechnology

Biotechnology is undoubtedly the technology of the future for it not only presents exceptional opportunities, but also gives hope for a better future with better diagnosis and treatment of diseases. In terms of potential and growth, it is not much different from the mystical dragon, and since 2012 is the year of the dragon, it is expected that it would bring in loads of good news and prosperity for this new branch of science.
The good news
For biotechnology, the last year has been strong and monumental with Tax Incentive Legislation being passed in Australia and a very strong and consistent growth in the sector which was recently followed by good news, the Senate Inquiry of the gene patents bill. Since the last year, the Australian Biotechnology has been included amongst the fifth most innovative biotech nations in the world (according to the Scientific American World View). This trend is continuing in the current year, as Australia has shown great potential in developing biotech related agricultural, medical and even environmental research.
The companies of Australian Biotech are confident that the New Year would definitely be the best and until now with tremendous growth in the sector it has proved this. Even the new startup biotech companies in Australia now stand a better chance with the Tax Incentive’s 45% refundable component, even the large corporations would now be able to reduce their R&D expenses by as much as 10%. Such a healthy growth favoring environment has allowed the Australian Biotech companies to make a mark globally and have a steadily rising status even in the competitive markets of US and Europe.
Conclusion
The Australian Biotech industry now needs to revamp itself and embrace a more authentic and transparent management. There should be better communication between the management and the stakeholders. The opportunities are in plenty and the industry environment very supportive, hence the companies should make the most of it and truly let the biotech dragon rise in this year of the dragon.

Source:
http://www.biotechblog.org/rss.xml